4,237 Shares in Danaher Corporation $DHR Purchased by Three Magnolias Financial Advisors LLC

Three Magnolias Financial Advisors LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 4,237 shares of the conglomerate’s stock, valued at approximately $939,000.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Danaher in the second quarter valued at approximately $10,492,520,000. Wellington Management Group LLP lifted its position in Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new stake in Danaher in the 2nd quarter valued at $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher in the 2nd quarter valued at $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher in the 2nd quarter worth $993,846,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Stock Up 0.9%

Shares of NYSE DHR traded up $1.94 during midday trading on Wednesday, reaching $224.78. The company’s stock had a trading volume of 2,001,034 shares, compared to its average volume of 4,449,140. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market capitalization of $158.02 billion, a price-to-earnings ratio of 39.91, a PEG ratio of 2.78 and a beta of 0.76. The stock has a 50 day simple moving average of $212.41 and a 200-day simple moving average of $195.13.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the firm posted $0.77 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DHR. Royal Bank Of Canada increased their target price on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Morgan Stanley lifted their price target on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Guggenheim boosted their price target on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Finally, The Goldman Sachs Group upped their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.